WT-1

WT-1
Name	WT-1
Caption	Wilms' tumor 1 protein
Uniprot	P19544
Gene	WT1
Organism	Homo sapiens

WT-1 WT-1 is a zinc finger transcription factor encoded by the WT1 gene that plays critical roles in embryonic development, urogenital ridge, kidney development, and gonadal differentiation. First characterized in studies of Wilms tumor and tumor suppressor biology, WT-1 functions in cell fate determination, RNA metabolism, and chromatin regulation across multiple tissues including the kidney, heart, and hematopoietic system. Its complex splicing, post-translational modification, and context-dependent activities link WT-1 to congenital syndromes, pediatric neoplasms, and adult malignancies.

Overview

WT-1 was discovered in positional cloning efforts for Wilms tumor alongside investigations by researchers at institutions such as St. Jude Children's Research Hospital and Harvard Medical School. The protein contains four C2H2 zinc fingers that mediate DNA and RNA interactions, and alternative splicing produces isoforms with distinct functions observed in studies at National Institutes of Health and Cold Spring Harbor Laboratory. WT-1 interacts with cofactors characterized in biochemical screens at Max Planck Institute and features in developmental gene regulatory networks elucidated by groups at Stanford University and University of Cambridge.

Genetics and Molecular Biology

The WT1 gene resides on human chromosome 11p13, a locus implicated by cytogenetic mapping efforts involving Human Genome Project consortia and linkage studies led by Genome Research Limited investigators. WT1 encodes multiple isoforms arising from alternative splicing at exon 9 (KTS insertion) and alternative translation initiation described in publications from Cambridge University Press and laboratories at Massachusetts Institute of Technology. WT-1 binds GC-rich promoter motifs and interacts with chromatin remodelers such as members of the SWI/SNF complex and transcriptional regulators identified in proteomics screens at European Molecular Biology Laboratory and Broad Institute. Post-translational modifications, including SUMOylation and phosphorylation by kinases studied at Max Planck Institute of Biochemistry and Johns Hopkins University, modulate WT-1 stability and subnuclear localization. WT-1 regulates target genes including IGF2, PDGFA, and components of the WNT signaling pathway uncovered in experiments at University of California, San Francisco and Yale University.

Clinical Significance and Disease Associations

Germline mutations at 11p13 were first linked to predisposition to Wilms tumor in pediatric oncology cohorts at Children's Hospital Boston and Great Ormond Street Hospital. WT1 mutations cause syndromic disorders such as Denys-Drash syndrome, Frasier syndrome, and WAGR syndrome, with clinical correlations established by case series from Mayo Clinic and Cleveland Clinic. Somatic WT1 alterations are reported in leukemias studied by consortia including The Cancer Genome Atlas and European LeukemiaNet, and in solid tumors analyzed by researchers at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. WT-1 autoantibodies and WT-1 peptide expression serve as biomarkers in trials run by groups at MD Anderson Cancer Center and Fred Hutchinson Cancer Center.

Diagnostic Methods

Molecular diagnostics for WT1 involve sequencing approaches developed by companies such as Illumina and research centers like Wellcome Sanger Institute using panels validated against datasets from ClinVar and COSMIC. Immunohistochemistry employing WT-1 antibodies is routine in pathology laboratories at Royal College of Pathologists and American Society of Clinical Pathology-accredited centers to distinguish neoplasms including mesothelioma and serous ovarian carcinoma identified in studies at Johns Hopkins Hospital and Princess Margaret Cancer Centre. Quantitative PCR assays for WT1 transcripts are used for minimal residual disease monitoring in acute myeloid leukemia in protocols from European Hematology Association and American Society of Hematology. Cytogenetic analysis of 11p13 deletion is performed in genetics units at Children's National Hospital and GeneDx.

Treatment and Management

Management of WT1-associated conditions integrates surgical, chemotherapeutic, and surveillance strategies refined by pediatric oncology consortia such as SIOP and COG. Nephrectomy and nephron-sparing surgery guidelines are informed by clinical trials at International Society of Paediatric Oncology and centers like St. Jude Children's Research Hospital. WT1-targeted immunotherapy, including peptide vaccines and T-cell receptor–engineered therapies, have been developed in translational programs at National Cancer Institute, University of Pennsylvania, and industry partners including Novartis and Gilead Sciences. For syndromic patients with gonadal dysgenesis or nephropathy, multidisciplinary care protocols from European Society of Paediatric Nephrology and Endocrine Society centers guide endocrine, renal, and oncologic surveillance.

Research and Experimental Models

Animal and cellular models have been pivotal: knockout and conditional alleles in mice generated by teams at Jackson Laboratory and Wellcome Trust Sanger Institute revealed roles in nephrogenesis and cardiac morphogenesis; zebrafish models from Max Planck Institute and University of Oxford labs elucidated WT-1 functions in pronephros development. Human induced pluripotent stem cell and organoid models developed at RIKEN and Harvard Stem Cell Institute recapitulate WT1-dependent differentiation of podocytes and gonadal lineages. High-throughput screens at Broad Institute and structural studies at European Synchrotron Radiation Facility inform drug discovery efforts targeting WT1 interactions. Collaborative initiatives including projects at Horizon 2020 and research networks supported by National Institutes of Health sustain ongoing translational work.

Category:Proteins